Interim report January – September 2024 for CombiGene AB (publ)

July – September 2024
• Net sales: TSEK 0 (992).
• Other operating revenues: TSEK 793 (173).
• Profit from financial items: TSEK -8,959 (-8,403).
• Earnings per share: SEK -0.45 (-0.42).

January – September 2024
• Net sales: TSEK 326 (4,948).
• Other operating revenues: TSEK 1,347 (588).
• Profit from financial items: TSEK -30,720 (-29,305).
• Earnings per share: SEK -1.55 (-1.48).
• Cash and cash equivalents: TSEK 76,685 (107,187).

Events during the period
• CombiGene announces new preclinical research results in the epilepsy project, CG01.
• Västra Hamnen takes over as Certified Adviser on 25 August 2024.
• The rights to the lipodystrophy project, CGT2, have returned to Lipigon on August 5, 2024, and the project has been
terminated.

Events after the end of the period
• CombiGene initiates measures to extend the liquidity horizon by sharpening the strategic focus on gene therapy
and implementing a cost reduction program.

Share